Immunotherapy in cancer is a type of treatment discovered in the 1970s, with the onset of bladder cancer therapy with BCG and IFN therapy in malignant melanoma. Various immune therapies such as IL 2 cytokine used in solid tumours like melanoma were discovered. A period of decline of these therapies followed, with powerful side effects and minor results. Along with studying the mechanisms of the immune response, there are cells involved in the immune response, mediators that cause stimulation or inhibition of the immune response, developing new therapies. Cancer immunotherapy involves the use of therapeutic modalities that lead to a manipulation of the immune system by using immune agents such as cytokines, vaccines, cell therapies, and transfection agents.

Immunotherapy of cancer: stimulates the host’s anti-tumour response by increasing the effector cell number (like DC based vaccines) and production of soluble mediators (like increased tumour cell immunogenicity) and decreases the host’s suppressor mechanisms by inducing tumour killing environment and by modulating immune checkpoints. Cancer immunotherapy presupposes treatments that enhance the innate powers of the immune system to fight cancer and represents the most promising new cancer treatment.

The scope and discipline of Immunological Disorders and Immunotherapy (ISSN: 2593-8509) is very broad which includes immune disorders caused by genetic variation related to monogenic as well as polygenic disorders, due to immune system over expressive or deformities, wide range of congenital or acquired disorders.

All proposals should be submitted to  www.longdom.org/submissions/immunological-disorders-immunotherapy.html